Merus NV(MRUS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRUS Merus NV

Market Closed 12-12 16:00:00 EST

96.93

+0.30

+0.31%

盘后96.93

+0.000.00%

16:10 EST

High96.94	Low96.80	Vol708.55K
Open96.80	D1 Closing96.63	Amplitude0.14%
Mkt Cap7.35B	Tradable Cap6.36B	Total Shares75.85M
T/O68.67M	T/O Rate1.08%	Tradable Shares65.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MRUS","market":"US","secType":"STK","nameCN":"Merus NV","latestPrice":96.93,"timestamp":1765573200000,"preClose":96.63,"halted":0,"volume":708546,"hourTrading":{"tag":"盘后","latestPrice":96.93,"preClose":96.93,"latestTime":"16:10 EST","volume":1657,"amount":160611.65,"timestamp":1765573804054},"delay":0,"floatShares":65607927,"shares":75847175,"eps":-5.361263,"marketStatus":"Market Closed","change":0.3,"latestTime":"12-12 16:00:00 EST","open":96.8,"high":96.94,"low":96.8,"amount":68665529.9799,"amplitude":0.001449,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.361263,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1463630400000,"exchange":"NASDAQ","adjPreClose":96.63,"preHourTrading":{"tag":"盘前","latestPrice":96.8,"preClose":96.63,"latestTime":"09:29 EST","volume":1828,"amount":176823.15292,"timestamp":1765549754144},"postHourTrading":{"tag":"盘后","latestPrice":96.93,"preClose":96.93,"latestTime":"16:10 EST","volume":1657,"amount":160611.65,"timestamp":1765573804054},"volumeRatio":0.5132636537814574,"optionData":{"bulkOrders":[{"symbol":"MRUS","call":false,"expireDate":1766120400000,"strike":"70.0","timestamp":1765553130904,"price":0.05,"volume":2000,"amount":10000,"type":"-"}]},"impliedVol":0.2896,"impliedVolPercentile":0.172},"requestUrl":"/m/hq/s/MRUS","defaultTab":"news","newsList":[{"id":"2590057359","title":"Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590057359","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590057359?lang=en_us&edition=fundamental","pubTime":"2025-12-12 15:02","pubTimestamp":1765522931,"startTime":"0","endTime":"0","summary":"Dec 12 (Reuters) - Genmab A/S ::*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD*EXPECTS TO LAUNCH PETOSEMTAMAB I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nRSD2zqMD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","LU0889565916.HKD","MRUS","LU0109394709.USD"],"gpt_icon":0},{"id":"2590679578","title":"Genmab Completes Tender Offer for Merus Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590679578","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590679578?lang=en_us&edition=fundamental","pubTime":"2025-12-12 14:35","pubTimestamp":1765521341,"startTime":"0","endTime":"0","summary":"Genmab has completed the tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share in cash. With this transaction, Genmab adds petosemtamab-a late-stage asset with two Breakthrough Therapy Designations-to its portfolio. The addition of petosemtamab is expected to accelerate Genmab's shift to a wholly owned model, expand and diversify revenue, and contribute to sustained growth. The company anticipates the deal will be accretive to its EBITDA by the end of 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3bZhfF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","MRUS","IE00BGHQF748.EUR","LU0109394709.USD","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4585","LU2210150020.SGD","BK4139","SG9999014021.USD","NDAQ","SG9999014039.USD","BK4588","LU2210149790.SGD","LU0320765992.SGD","LU2095319765.USD","BK4112","LU0889565916.HKD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2590321166","title":"Merus NV Held Extraordinary General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321166","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321166?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314104,"startTime":"0","endTime":"0","summary":"Merus NV held an extraordinary general meeting of shareholders on December 9, 2025. Shareholders approved the proposals related to the back-end transactions under the transaction agreement with Genmab, including the statutory merger with Merus Merger B.V. The appointment of Greg Mueller, Anthony Pagano, and Martine van Vugt, Ph.D. as non-executive directors was also approved. Another proposal referenced a Dutch tax ruling, which was obtained prior to the meeting and therefore rendered the proposal moot.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLc52CXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRUS","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2588029671","title":"Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588029671","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588029671?lang=en_us&edition=fundamental","pubTime":"2025-12-04 04:03","pubTimestamp":1764792205,"startTime":"0","endTime":"0","summary":"Genmab A/S has completed the closing of a previously announced private offering, raising $1.5 billion through 6.250% senior secured notes due 2032 and $1.0 billion through 7.250% senior unsecured notes due 2033. The company plans to use the proceeds from this offering, along with funds from new credit facilities and cash on hand, to finance the pending acquisition of Merus N.V. and cover related fees and expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL6BzNN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","NDAQ","BK4139","BK4588","LU2095319765.USD","LU0889565916.HKD","IE00B3QW5Z07.USD","MRUS","LU0314104364.USD","BK4585","IE00BKPKM429.USD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2586617952","title":"Merus (MRUS): Evaluating the Biotech’s Valuation After a 127% Year-to-Date Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2586617952","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586617952?lang=en_us&edition=fundamental","pubTime":"2025-11-26 23:32","pubTimestamp":1764171142,"startTime":"0","endTime":"0","summary":"Merus (MRUS) has quietly posted some interesting long-term returns, raising questions about how this biotech stock’s value stacks up after recent moves. Despite market ups and downs, the past year has seen dramatic changes.\nSee our latest analysis for Merus.\nMerus has seen its share price climb an impressive 127% year-to-date, with a sharp 42.7% surge over the last 90 days. This signals that momentum is still very much alive. The one-year total shareholder return sits north of 100%,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/merus-mrus-evaluating-the-biotechs-valuation-after-a-127-yea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/merus-mrus-evaluating-the-biotechs-valuation-after-a-127-yea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU0109394709.USD","LU0889565916.HKD","MRUS","LU0320765992.SGD"],"gpt_icon":0},{"id":"2584965653","title":"Genmab Prices $2.5 Billion in Notes to Fund Acquisition of Merus","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965653","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965653?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:01","pubTimestamp":1763499684,"startTime":"0","endTime":"0","summary":"Genmab A/S and its wholly owned subsidiary Genmab Finance LLC have priced an offering of $1.5 billion in 6.250% senior secured notes due 2032 and $1.0 billion in 7.250% senior unsecured notes due 2033, with an issue price of 100%. The company has also completed the syndication of a new $2.0 billion senior secured term loan \"B\" facility, in addition to previously syndicated $1.0 billion senior secured term loan \"A\" facility and a $500 million senior secured revolving credit facility. Genmab intends to use the net proceeds from the new notes, the credit facilities, and cash on hand to fund the acquisition of Merus N.V., as well as related fees and expenses. The offering is expected to close on December 3, 2025, subject to customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL907GgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0314104364.USD","LU2210150020.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","LU0109394709.USD","MRUS","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2584164072","title":"Halozyme Signs Global License Agreement With Merus for Subcutaneous Petosemtamab","url":"https://stock-news.laohu8.com/highlight/detail?id=2584164072","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584164072?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:01","pubTimestamp":1763380902,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics Inc. and Merus N.V. have entered into a global non-exclusive collaboration and license agreement. Under the terms of the agreement, Merus will make an upfront payment to Halozyme, with potential future milestone payments related to commercial and sales attainment if approved. Halozyme will also be entitled to receive up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term. The collaboration grants Merus a license to use Halozyme's ENHANZE drug delivery technology for the development and potential commercialization of a subcutaneous formulation of petosemtamab, an EGFR x LGR5 bispecific antibody.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL6pfPBb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","MRUS","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","HALO"],"gpt_icon":0},{"id":"2583576596","title":"Did Rising Nine-Month Losses and Modest Revenue Growth Just Shift Merus' (MRUS) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583576596","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583576596?lang=en_us&edition=fundamental","pubTime":"2025-11-14 13:31","pubTimestamp":1763098306,"startTime":"0","endTime":"0","summary":"Merus N.V. reported its third quarter 2025 earnings, showing revenue of US$12.15 million and a net loss of US$95.52 million, with the nine-month loss rising to US$350.21 million on revenue of US$47.47 million.\nWhile quarterly revenues edged up from last year, losses for the nine-month period grew dramatically as reported on October 31, 2025.\nWe'll examine how Merus' ramp-up in nine-month revenues alongside widening losses shapes its current investment narrative.\nThe end of cancer? These 29...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/did-rising-nine-month-losses-and-modest-revenue-growth-just","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/did-rising-nine-month-losses-and-modest-revenue-growth-just","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MRUS"],"gpt_icon":0},{"id":"2582875256","title":"Genmab Announces Proposed Private Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875256?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:26","pubTimestamp":1762777604,"startTime":"0","endTime":"0","summary":"Nov 10 (Reuters) - Genmab A/S ::*TO OFFER $1.5 BILLION SENIOR SECURED NOTES DUE 2032*TO OFFER $1.0 BILLION SENIOR UNSECURED NOTES DUE 2033*LAUNCHES $2.0 BILLION SENIOR SECURED TERM LOAN 'B' FACILITY*T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nRSD10N1mg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139","MRUS"],"gpt_icon":0},{"id":"2582875588","title":"Genmab Launches $4.5 Billion Financing to Acquire Merus","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875588?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:17","pubTimestamp":1762777063,"startTime":"0","endTime":"0","summary":"Genmab A/S and its wholly owned subsidiary Genmab Finance LLC plan to raise $1.5 billion in senior secured notes due 2032 and $1.0 billion in senior unsecured notes due 2033, along with the syndication of a new $2.0 billion senior secured term loan \"B\" facility. These financing efforts, which build on previously syndicated credit facilities totaling $1.5 billion, are intended to fund the pending acquisition of Merus N.V., including related fees and expenses. Proceeds from the notes, new credit facilities, and existing cash will be used to cover the acquisition costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL65pvn2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4588","LU0109394709.USD","BK4139","MRUS","LU2095319765.USD","LU2210149790.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0889565916.HKD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2581592268","title":"Assessing Merus (MRUS) Valuation After Its Recent Surge in Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2581592268","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581592268?lang=en_us&edition=fundamental","pubTime":"2025-11-08 12:47","pubTimestamp":1762577270,"startTime":"0","endTime":"0","summary":"Merus (MRUS) has caught the attention of many investors after its stock saw significant gains over the past month, as well as even more dramatic growth during the past quarter. This rally raises new questions about its current valuation.\nSee our latest analysis for Merus.\nMerus’s recent 90-day share price return of 48.8% is part of a much larger trend, with the stock posting a year-to-date gain of 125.1%. While the stock has seen a series of noteworthy gains over the past quarter, its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/assessing-merus-mrus-valuation-after-its-recent-surge-in-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/assessing-merus-mrus-valuation-after-its-recent-surge-in-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","MRUS","LU0889565916.HKD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2581102090","title":"Genmab reports 21% revenue growth and 52% operating profit increase for first nine months of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581102090","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581102090?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:09","pubTimestamp":1762445342,"startTime":"0","endTime":"0","summary":"Genmab A/S reported total revenue of USD 3.1 billion for the full year 2024, reflecting a 21% increase for the first nine months of 2025 compared to the prior period. Operating profit grew by 52% over the same period. For 2024, operating profit was USD 972 million. Cash reserves stood at USD 3.4 billion. Net product sales and collaboration revenue include EPKINLY net product sales in the U.S. and Japan and Genmab's share of Tivdak net profits. Key business developments include focused investments in high-impact programs, key data presentations, and the proposed acquisition of Merus, with plans for the first launch of petosemtamab in 2027 and multiple ongoing Phase 3 studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S pub","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL20MmDG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","LU0320765992.SGD","MRUS","LU0889565916.HKD"],"gpt_icon":0},{"id":"2581309091","title":"Genmab to Acquire Merus for $8 Billion in All-Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2581309091","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581309091?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:02","pubTimestamp":1762444950,"startTime":"0","endTime":"0","summary":"Genmab intends to acquire all shares of Merus, a clinical-stage biotechnology company, for USD 97.00 per share in an all-cash transaction valued at approximately USD 8.0 billion. The deal is expected to be funded through a combination of cash on hand and around $5.5 billion in non-convertible debt financing, with funding commitments already secured. The transaction is anticipated to close by early in the first quarter of 2026, pending customary closing conditions. Merus' lead asset, petosemtamab, is currently in Phase 3 development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire  on November 06, 2025, and is solely responsible for the informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1PBsLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0314104364.USD","LU2210150020.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","LU0109394709.USD","MRUS","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2580241232","title":"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Merus (MRUS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580241232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580241232?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:40","pubTimestamp":1762195227,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV – Research Report) and Merus (MRUS – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-merus-mrus-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-merus-mrus-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1061106388.HKD","LU0965509010.AUD","LABU","BK4137","LU0170899867.USD","LU0689472784.USD","LU0889565916.HKD","IE00B2B36J28.USD","LU0949170772.SGD","LU0661504455.SGD","LU2129689514.USD","LU0417517546.SGD","LU2237443978.SGD","LU0211327993.USD","LU1267930573.SGD","ABBV","LU0432979614.USD","LU0912757837.SGD","XBI","LU0310800379.SGD","BK4559","BK4550","IE00BN8TJ469.HKD","LU2237443622.USD","MRUS","LU2087621335.USD","LU2129689431.USD","LU0203347892.USD","LU2237443382.USD","LU0553294199.USD","XLV","LU0320765646.SGD","LU1551013425.SGD","LU0124676726.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0256863811.USD","LU1003077747.HKD","LU1093756325.SGD","BK4566","LU0289739699.SGD","LU0158827948.USD","IE00BJT1NW94.SGD","HCSG","IE00BVYPNV92.GBP","LU2237443549.SGD","LU1732800096.USD","LU0689626769.HKD","LU1430594728.SGD","LU0198837287.USD"],"gpt_icon":0},{"id":"2580249971","title":"Truist Financial Reaffirms Their Hold Rating on Merus (MRUS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580249971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580249971?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:15","pubTimestamp":1762193755,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene reiterated a Hold rating on Merus today and set a price target of $97.00. The company’s shares opened...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-hold-rating-on-merus-mrus-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-hold-rating-on-merus-mrus-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRUS"],"gpt_icon":0},{"id":"2580047604","title":"Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2580047604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580047604?lang=en_us&edition=fundamental","pubTime":"2025-11-02 13:09","pubTimestamp":1762060153,"startTime":"0","endTime":"0","summary":"Merus NV (MRUS) has disclosed a new risk, in the Innovation / R&D category. Merus NV faces significant business risks due to its reliance on the un...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/merus-nvs-financial-stability-at-risk-due-to-unproven-adclonics-technology-and-supply-chain-vulnerabilities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/merus-nvs-financial-stability-at-risk-due-to-unproven-adclonics-technology-and-supply-chain-vulnerabilities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0109394709.USD","LU0889565916.HKD","MRUS","LU0320765992.SGD"],"gpt_icon":0},{"id":"2580412608","title":"Merus NV reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2580412608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580412608?lang=en_us&edition=fundamental","pubTime":"2025-11-01 06:31","pubTimestamp":1761949860,"startTime":"0","endTime":"0","summary":"Merus NV reports results for the quarter ended September 30 - Earnings SummaryMerus NV MRUS.OQ reported a quarterly adjusted loss of $1.26 per share for the quarter ended September 30, higher than the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC2KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4139","LU0109394709.USD","MRUS"],"gpt_icon":0},{"id":"2580416513","title":"Merus NV Announces Date for Extraordinary General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416513","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416513?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:24","pubTimestamp":1761942271,"startTime":"0","endTime":"0","summary":"Merus NV has scheduled an Extraordinary General Meeting for its shareholders. During the meeting, shareholders will have the opportunity to make recommendations to the company's non-executive directors regarding their nomination to appoint a non-executive director. The meeting will also include the proposed appointment of Martine van Vugt, Ph.D., as a non-executive director of Merus. Additionally, there will be a non-binding advisory proposal to approve certain compensation arrangements. Other business may also be addressed as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL5HcYv0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","MRUS","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2580912434","title":"Assessing Merus (MRUS) Valuation After This Year’s 120% Share Price Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2580912434","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580912434?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:41","pubTimestamp":1761914490,"startTime":"0","endTime":"0","summary":"Merus (MRUS) has seen impressive momentum this year, with shares climbing over 120% year-to-date. Recent performance has caught the eye of many investors, especially as biotech valuations continue to draw attention across the market.\nSee our latest analysis for Merus.\nThis surge in Merus’s share price is part of a months-long rally fueled by growing optimism around its clinical pipeline and positive sector momentum. Momentum is clearly building, with a year-to-date share price return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/assessing-merus-mrus-valuation-after-this-years-120-share-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrus/merus/news/assessing-merus-mrus-valuation-after-this-years-120-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","MRUS","LU0889565916.HKD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2577451011","title":"Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577451011","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577451011?lang=en_us&edition=fundamental","pubTime":"2025-10-24 22:40","pubTimestamp":1761316825,"startTime":"0","endTime":"0","summary":"Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/merus-to-present-interim-data-on-petosemtamab-at-aacr-nci-eortc-conference-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/merus-to-present-interim-data-on-petosemtamab-at-aacr-nci-eortc-conference-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4202","NCI","LU0109394709.USD","LU0889565916.HKD","MRUS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.merus.nl","stockEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.3931},{"period":"6month","weight":0.7749},{"period":"1year","weight":1.3385},{"period":"ytd","weight":1.3051}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.093783},{"month":2,"riseRate":0.555556,"avgChangeRate":0.063295},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.034321},{"month":4,"riseRate":0.555556,"avgChangeRate":0.005312},{"month":5,"riseRate":0.555556,"avgChangeRate":0.022377},{"month":6,"riseRate":0.6,"avgChangeRate":0.06743},{"month":7,"riseRate":0.5,"avgChangeRate":0.029651},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0088},{"month":9,"riseRate":0.5,"avgChangeRate":0.138868},{"month":10,"riseRate":0.5,"avgChangeRate":-0.032973},{"month":11,"riseRate":0.5,"avgChangeRate":0.006855},{"month":12,"riseRate":0.8,"avgChangeRate":0.078865}],"exchange":"NASDAQ","name":"Merus NV","nameEN":"Merus NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Merus NV(MRUS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Merus NV(MRUS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Merus NV,MRUS,Merus NV股票,Merus NV股票老虎,Merus NV股票老虎国际,Merus NV行情,Merus NV股票行情,Merus NV股价,Merus NV股市,Merus NV股票价格,Merus NV股票交易,Merus NV股票购买,Merus NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Merus NV(MRUS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Merus NV(MRUS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction